Key Highlights

  • Net loss for the third quarter widened to USD 20.8 million from USD 12.2 million, while the loss per share narrowed to USD 0.10 from USD 0.17 on a far larger share count.
  • Research and development expense rose to USD 15.7 million from USD 5.9 million, tied to the OV329 and OV4071 programs, while general and administrative expense was USD 6.7 million.
  • Cash, cash equivalents and marketable securities totaled USD 161.4 million at September 30, 2026, and management believes that funds its current operating plans for at least 12 months.
  • The company ended its Cowen at-the-market program on November 9, 2026 and signed a new USD 75.0 million at-the-market sales agreement with Cantor Fitzgerald the same day.

Wider Loss as Spending Shifts to Two Clinical Programs

Ovid Therapeutics (NASDAQ:OVID) filed its Quarterly Report on November 10, 2026 for the period ended September 30, 2026. The company recorded no Revenue in the quarter against USD 0.1 million a year earlier, so results track spending. Operating expenses were USD 22.4 million versus USD 12.7 million, and other income of USD 1.6 million, mostly interest on treasury holdings, partly offset the loss. The per-share loss fell because weighted shares rose to about 203.0 million from about 71.1 million. For nine months, net loss was USD 52.8 million, or USD 0.29 per share, versus USD 27.1 million, or USD 0.37.

OV329 and OV4071 Take Center Stage in R&D

The company develops small molecule medicines for epilepsy and other brain disorders. OV329, a GABA-aminotransferase inhibitor, is in a global Phase 2 study in drug-resistant focal epilepsy, and OV4071, an oral KCC2 activator, is in a Phase 1 study in healthy volunteers. Preclinical and clinical development expense jumped to USD 11.6 million from USD 3.5 million. Revenue for nine months was USD 0.7 million tied to a soticlestat agreement with NewCo, down from USD 6.5 million of Royalty and licensing revenue, so the company has little income to offset the spending ramp, and G&A costs included severance and recruiting expenses in the nine-month period.

Funding Moves: Warrant Proceeds, a New ATM and Dilution

Net cash used in Operating Activities was USD 47.4 million for nine months versus USD 27.9 million. The company raised money through a March 2026 private Placement with net proceeds of USD 56.2 million and Series A warrant exercises that brought in USD 50.6 million after expenses. It also sold 5.0 million shares through the Cowen program for about USD 10.5 million, then replaced it with the Cantor facility, with sales at its option. Series B warrants could add up to USD 40.0 million. Issuing shares dilutes holders, and the filing says milestone obligations under in-licenses could reach USD 279.3 million.

Where Things Stand

For at least a year, according to management, but not indefinitely. Ovid Therapeutics (NASDAQ:OVID) holds USD 161.4 million, no material long-term Debt and Working Capital of USD 130.1 million, against nine-month cash burn from operations of USD 47.4 million. Spending is rising as OV329 and OV4071 advance, and the accumulated Deficit is USD 374.5 million. The filing says the company depends on finding additional equity, debt or licensing funding, and it does not expect further revenue unless a candidate wins approval. Next markers are clinical progress on both programs and use of the new at-the-market facility.